BG-75098 is an orally bioavailable chimeric degradation activation compound that binds CDK2 and an E3 ubiquitin ligase, driving ubiquitination and proteasomal degradation of CDK2. By reducing CDK2 activity, it inhibits Rb phosphorylation and blocks the G1/S transition. It is being studied in advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
At a glance
Drug type
Small molecule
Targets
cyclin-dependent kinase 2 (CDK2), cyclin E1 (CCNE1) (binding partner it blocks), retinoblastoma protein (RB1) (binding partner it blocks)
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.